Hansa Biopharma has announced positive complete results from its single arm 15-HMedIdeS-09 Phase II study on the use of imlifidase for the treatment of the rare disease Guillain-Barré syndrome (GBS). The company conducted an indirect treatment comparison analysis of 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by […]
Sign up for our newsletters and receive webinars, vitals and updates for your topic of choice.
Please review our privacy policy and understand that we may occasionally inform you of similar content if you press submit to subscribe to a newsletter. You may unsubscribe at anytime.